- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00280228
Home Based Treatment for Drug Use in Early Adolescents
Home-based Behavioral Therapy (HBT): Psychosocial Intervention Project for Early Adolescents With Pre- or Early Substance Use Disorder: Phase II
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In this study phase, 36 patients with a disruptive behavior disorder (DBD - i.e., attention deficit-hyperactivity disorder, oppositional defiant disorder, conduct disorder) and use or abuse of one or more substances will be randomly assigned to treatment using either a standard treatment for DBDs in this age group or the newly developed HBT treatment. Treatment outcomes for the 24 patients assigned to receive HBT will then be compared to outcomes for the 12 patients assigned to receive standard DBD treatment.
Specific aims of Phase II include:
- finalizing the HBT treatment manual and measures of treatment fidelity, therapist competence, and treatment satisfaction;
- generating estimates of treatment effect sizes for substance use, disruptive behavior, and functional status outcomes, as pilot data for a larger efficacy study, and
- comparing treatment satisfaction for the two treatment groups.
We hypothesize that HBT will lead to significantly lower rates of disruptive behaviors, substance use, and SUDs than with standard treatment, as well as greater concomitant improvements in impairment.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Youth and Family Research Program
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Study participants (subjects and parents) must provide written consent and verbal assent
- Adolescents aged 11 through 14 of any race or ethnic background,
- A DSM-IV disruptive behavior disorder diagnosis (either CD, ODD, ADHD or disruptive behavior disorder not otherwise specified [DBD NOS]),
- Adolescents who are either using one or more substances regularly (2 or more times a month for 3 consecutive months), and
- Acceptable insurance coverage (i.e., participant has insurance that is accepted by the University of Pittsburgh Medical Center [UPMC] in the event that they are randomly assigned to the treatment-as-usual [TAU] group).
Exclusion Criteria:
- Full scale IQ below 80;
- History of pervasive developmental disorder, schizophrenia or other psychotic disorders, organic mental disorders or eating disorders,
- Diagnosis of bipolar disorder,
- Recent treatment for substance problems, and/or
- Daily use of "hard" street drugs (i.e., cocaine, methamphetamine, heroin, inhalants).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
Home Based Treatment
|
Acute treatment for 12 weeks followed by three monthly booster sessions.
|
Active Comparator: 2
Treatment as Usual
|
Standard outpatient treatment for behavioral problems and substance use
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rates of substance use and disruptive behaviors
Time Frame: immediately following acute 12 week treatment, at the end of 3 month followup, and at one year follow up
|
immediately following acute 12 week treatment, at the end of 3 month followup, and at one year follow up
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Oscar G Bukstein, M.D., M.P.H., University of Pittsburgh
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DA016631
- 5R21DA016631 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Attention Deficit Hyperactivity Disorder
-
Cingulate TherapeuticsRecruitingPhase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301ADHD | Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit HyperactivityUnited States
-
Ornit CohenUnknownAttention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | Attention Deficit Disorder | Attention Deficit Disorders With Hyperactivity | Attention Deficit Hyperactivity DisordersIsrael
-
Cingulate TherapeuticsPremier Research Group plcActive, not recruitingADHD | Attention Deficit Hyperactivity Disorder | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit HyperactivityUnited States
-
Children's National Research InstituteRecruitingADHD | Attention Deficit Hyperactivity Disorder | Attention-Deficit Hyperactivity Disorder | Attention Deficit Disorder | ADD | ADHD Predominantly Inattentive Type | ADHD - Combined Type | ADHD, Predominantly Hyperactive - Impulsive | Attention-Deficit Disorder in Adolescence | Attention-Deficit Hyperactivity...United States
-
Fondation LenvalCompletedAttention Deficit Disorder With Hyperactivity | Attention Deficit Disorder Without HyperactivityFrance
-
University Hospital Bispebjerg and FrederiksbergMental Health Services in the Capital Region, DenmarkRecruitingSleep Disturbance | Neurodevelopmental Disorders | Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder | Attention-Deficit Hyperactivity Disorder, Unspecified Type | Attention-deficit Hyperactivity | Hyperkinetic Conduct DisorderDenmark
-
Corium, Inc.Worldwide Clinical Trials; Premier Research Group plc; Almac; Prometrika, LLCRecruitingAttention Deficit/Hyperactivity DisorderUnited States
-
Corium, Inc.Premier Research Group plc; Almac; Prometrika, LLCRecruitingAttention Deficit/Hyperactivity DisorderUnited States
-
Massachusetts General HospitalShire Human Genetic Therapies, Inc.Active, not recruitingAttention Deficit/Hyperactivity DisorderUnited States
-
Ataturk UniversityCompletedAttention-deficit/Hyperactivity DisorderTurkey
Clinical Trials on Adolescent Skills Parent Management Parent-Adol Negotiation
-
Oregon Social Learning CenterNational Institute on Drug Abuse (NIDA)CompletedParent Management TrainingUnited States
-
Eunice Kennedy Shriver National Institute of Child...Completed
-
University of PennsylvaniaNational Institute of Mental Health (NIMH)CompletedDepression | AnxietyUnited States
-
Universitätsklinikum Hamburg-EppendorfRecruitingParent-Child RelationsGermany
-
Oregon Social Learning CenterNational Institute of Mental Health (NIMH)CompletedChild Welfare | Foster Home CareUnited States
-
San Diego State UniversityNational Institute of Mental Health (NIMH); Oregon Social Learning CenterCompletedBehavior ProblemsUnited States
-
Boston Children's HospitalCompleted
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)CompletedDisruptive Behavior DisordersUnited States
-
Yale UniversityCompletedAnger | Irritable Mood | Disruptive Behavior | Aggression Childhood | Non-Compliance, PatientUnited States
-
University of MichiganNational Institute of Nursing Research (NINR)CompletedHIV/AIDS | Pregnancy | STDUnited States